Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na)

13 Apr 2023

Abstract excerpt

Rigosertib (ON-01910.Na) is a small-molecule member of the novel synthetic benzyl-styryl-sulfonate family. It is currently in phase III clinical trials for several myelodysplastic syndromes and leukemias and is therefore close to clinical translation. The clinical progress of rigosertib has been hampered by a lack of understanding of its mechanism of action, as it is currently considered a multi-target inhibitor....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer-related Molecular Pathways
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37111716
DOI: 10.3390/pharmaceutics15041232

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na)PMID 37111716Read ↗

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer TreatmentSemantic proximity Read ↗

Rigosertib induces cell death of a myelodysplastic syndrome‐derived cell line by <scp>DNA</scp> damage‐induced G2/M arrestSemantic proximity Read ↗

A review of Plks: Thinking outside the (polo) boxSemantic proximity Read ↗

PLK-1 Targeted Inhibitors and Their Potential against TumorigenesisSemantic proximity Read ↗

Evolution of PIKK family kinase inhibitors A new age cancer therapeuticsSemantic proximity Read ↗

Strategies and techniques for preclinical therapeutic targeting of PI3K in oncology: where do we stand in 2024?Semantic proximity Read ↗

Mechanism of action of rigosertib does not involve tubulin bindingSemantic proximity Read ↗

Thoughts on the current assessment of Polo-like kinase inhibitor drug discoverySemantic proximity Read ↗

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in OncologySemantic proximity Read ↗

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeuticsSemantic proximity Read ↗

Present and Future Perspective on PLK1 Inhibition in Cancer TreatmentSemantic proximity Read ↗

Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.